Increased azithromycin susceptibility of multidrug-resistant gram-negative bacteria on RPMI-1640 agar assessed by disk diffusion testing by Meerwein, Milton et al.








Increased azithromycin susceptibility of multidrug-resistant gram-negative
bacteria on RPMI-1640 agar assessed by disk diffusion testing
Meerwein, Milton ; Tarnutzer, Andrea ; Böni, Michelle ; Van Bambeke, Françoise ; Hombach, Michael ;
Zinkernagel, Annelies S
Abstract: Increasing antibiotic resistances and a lack of new antibiotics render the treatment of Gram-
negative bacterial infections increasingly difficult. Therefore, additional approaches are being investi-
gated. Macrolides are not routinely used against Gram-negative bacteria due to lack of evidence of in
vitro effectiveness. However, it has been shown that Pseudomonas spp. are susceptible to macrolides in
liquid RPMI-1640 and clinical data suggest improvement in patients’ outcomes. So far, these findings
have been hardly applicable to the clinical setting due to lack of routine low-complexity antimicrobial sus-
ceptibility testing (AST) for macrolides. We therefore optimized and compared broth microdilution and
disk diffusion AST. Multidrug-resistant Gram-negative bacteria (Escherichia coli, Enterobacter cloacae,
Klebsiella pneumoniae, Pseudomonas aeruginosa) were tested for azithromycin susceptibility by disk dif-
fusion and broth microdilution in Mueller-Hinton and RPMI-1640 media. Azithromycin susceptibility of
Enterobacteriaceae and a subgroup of P. aeruginosa increased significantly on RPMI-1640 agar compared
to Mueller-Hinton agar. Further, a significant correlation (Kendall, ฀, p) of zone diameters and minimal
inhibitory concentrations (MICs) was found on RPMI-1640 agar for E. coli (-0.4279, 0.0051), E. cloacae
(-0.3783, 0.0237) and P. aeruginosa (-0.6477, <0.0001). Performing routine disk diffusion AST on RPMI-
1640 agar may lead to the identification of additional therapeutic possibilities for multidrug-resistant
bacterial infections in the routine clinical diagnostic setting.
DOI: https://doi.org/10.3390/antibiotics9050218






The following work is licensed under a Creative Commons: Attribution 4.0 International (CC BY 4.0)
License.
Originally published at:
Meerwein, Milton; Tarnutzer, Andrea; Böni, Michelle; Van Bambeke, Françoise; Hombach, Michael;
Zinkernagel, Annelies S (2020). Increased azithromycin susceptibility of multidrug-resistant gram-negative




Increased Azithromycin Susceptibility of
Multidrug-Resistant Gram-Negative Bacteria on
RPMI-1640 Agar Assessed by Disk Diffusion Testing
Milton Meerwein 1,† , Andrea Tarnutzer 1,†, Michelle Böni 1, Françoise Van Bambeke 2 ,
Michael Hombach 3,‡ and Annelies S. Zinkernagel 1,*
1 Department of Infectious Diseases and Hospital Epidemiology, University of Zurich, 8091 Zurich,
Switzerland; milton@meerwe.in (M.M.); andrea.tarnutzer@usz.ch (A.T.); michelle.boeni@uzh.ch (M.B.)
2 Pharmacologie cellulaire et moléculaire, Louvain Drug Research Institute, Université catholique de Louvain,
B-1200 Brussels, Belgium; francoise.vanbambeke@uclouvain.be
3 Institute of Medical Microbiology, University of Zurich, 8091 Zurich, Switzerland;
michael.hombach@roche.com
* Correspondence: annelies.zinkernagel@usz.ch
† These authors contributed equally to this work.
‡ Current address: Michael Hombach, Roche Diagnostics International AG, 6343 Rotkreuz, Switzerland.
Received: 20 March 2020; Accepted: 26 April 2020; Published: 29 April 2020


Abstract: Increasing antibiotic resistances and a lack of new antibiotics render the treatment of
Gram-negative bacterial infections increasingly difficult. Therefore, additional approaches are being
investigated. Macrolides are not routinely used against Gram-negative bacteria due to lack of
evidence of in vitro effectiveness. However, it has been shown that Pseudomonas spp. are susceptible
to macrolides in liquid RPMI-1640 and clinical data suggest improvement in patients’ outcomes.
So far, these findings have been hardly applicable to the clinical setting due to lack of routine
low-complexity antimicrobial susceptibility testing (AST) for macrolides. We therefore optimized
and compared broth microdilution and disk diffusion AST. Multidrug-resistant Gram-negative
bacteria (Escherichia coli, Enterobacter cloacae, Klebsiella pneumoniae, Pseudomonas aeruginosa) were tested
for azithromycin susceptibility by disk diffusion and broth microdilution in Mueller–Hinton and
RPMI-1640 media. Azithromycin susceptibility of Enterobacteriaceae and a subgroup of P. aeruginosa
increased significantly on RPMI-1640 agar compared to Mueller–Hinton agar. Further, a significant
correlation (Kendall, τ, p) of zone diameters and minimal inhibitory concentrations (MICs) was found
on RPMI-1640 agar for E. coli (−0.4279, 0.0051), E. cloacae (−0.3783, 0.0237) and P. aeruginosa (−0.6477,
<0.0001). Performing routine disk diffusion AST on RPMI-1640 agar may lead to the identification of
additional therapeutic possibilities for multidrug-resistant bacterial infections in the routine clinical
diagnostic setting.
Keywords: azithromycin; Gram-negative; Pseudomonas aeruginosa; Enterobacteriaceae; susceptibility
testing; MIC; disk diffusion; multidrug-resistant
1. Introduction
Increasing bacterial resistance to antibiotics and a lack of new antimicrobial compounds render
the treatment of bacterial infections more and more difficult [1]. One example is the rise of pathogens
carrying multidrug resistance (MDR) plasmids that confer resistance even against last-resort antibiotics
such as carbapenems and colistin. Treatment options for such MDR isolates are extremely limited
and the development of new drugs has almost come to a halt over the last two decades [2]. As an
alternative approach, old drugs such as fosfomycin or nitrofurantoin, which display a favorable
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epidemiologic susceptibility profile due to infrequent use and concomitant low selection pressure,
have been revived. Another approach would be to reconsider susceptibility testing methods for their
actual ability to predict the in vivo effectiveness of established drugs against bacterial groups that
are currently considered naturally resistant. An example are macrolides which are considered to be
active against Gram-positive infections; in clinics they are often used in patients with acute lower
respiratory tract infections [3]. Resistances against macrolides in Gram-positive bacteria are often
due to methylation or mutations in domain V of the 23S rRNA gene, which is targeted by macrolides,
or active efflux [4]. In contrast, most Gram-negative bacteria are considered intrinsically resistant to
macrolides, as their outer membrane is highly impermeable to hydrophobic substances and possesses
very efficient efflux pump systems [5,6]. While macrolides possess good activity against a few distinct
Gram-negative microorganisms, such as Bartonella spp. or Campylobacter spp., they are less effective
in Enterobacteriaceae [7,8]. Nevertheless, clinical trials suggest that macrolides could improve the clinical
outcome of patients with Gram-negative infections [9,10]. A meta-analysis showed an improved
clinical outcome in cystic fibrosis patients routinely treated with macrolides, an effect attributed to
immunomodulatory effects [11].
Antimicrobial susceptibility testing (AST) follows Kirby–Bauer’s original disk diffusion technique
by growing bacteria on cation-adjusted Mueller–Hinton (MH) agar plates, a comparably rich growth
medium ensuring sufficient bacterial growth and reproducible results [12]. As azithromycin is
not a standard treatment option for Gram-negative infections, susceptibility data and clinical
breakpoints have not been published by the European Committee on Antimicrobial Susceptibility
Testing (EUCAST) [13]. In contrast with the other macrolides, azithromycin has been shown to be more
basic in character, which results in higher permeability across the outer membrane [7]. Thus, recently,
a putative minimal inhibitory concentration (MIC) epidemiological cut-off value (ECOFF) of ≥32 mg/L
was suggested for Escherichia coli using agar dilution according to the Clinical and Laboratory Standards
Institute (CLSI), in order to discriminate wild-type from increased efflux or decreased permeability
isolates, and to provide a decision rationale for alternative treatment of diarrheal infections [14].
Bacterial growth media have not been modelled to reflect the physiological situation in the patient
but rather to ensure sufficient in vitro growth and reproducibility. Thus, AST in human serum or
lung fluids would be ideal but is not feasible in a routine setting. Eukaryotic growth medium has
been proposed as an alternative. Recent studies showed that azithromycin MICs were lower in the
eukaryotic growth medium Roswell Park Memorial Institute 1640 (RPMI-1640) [15–17] or Dulbecco
Modified Eagle Medium (DMEM) as compared to MH medium [18]. Thus, modifying in vitro AST
parameters in order to more closely mirror in vivo conditions may reveal additional treatment options
for Gram-negative MDR infections [19]. The goal of this study was, hence, to transfer those observations
into a routine clinical microbiology setting. As in diagnostics, antibiotic susceptibility is mostly assessed
by agar-based disk diffusion testing; we evaluated a quick and simple method for AST by developing
a disk diffusion assay on RPMI-1640 agar. This allows to routinely assess the antimicrobial activity of
azithromycin against various Gram-negative bacteria.
2. Results
2.1. Enterobacteriaceae Showed Enhanced Azithromycin Susceptibility on RPMI-1640 Agar
Median azithromycin inhibition zones of Enterobacteriaceae (E. coli, K. pneumoniae and E. cloacae)
were significantly larger on RPMI-1640 agar plates as compared to standard MH plates (median
diameter increase of 7–8 mm (Table 1)).
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Table 1. Median azithromycin inhibition zone diameters of Enterobacteriaceae and P. aeruginosa on
Mueller–Hinton (MH) and RPMI-1640 agar.
Family Species n MH [mm] RPMI-1640 [mm]
E. coli 28 15.5 (12–17) 24 (18.5–26.75) ***
Enterobacteriaceae E. cloacae 24 9 (6–11) 17.5 (15.25–19) ***
K. pneumoniae 26 11.5 (9–12.25) 19 (16.75–21) ***
Pseudomonadaceae P. aeruginosa 55 6 (6–7) 9 (7–15) ***
Azithromycin inhibition zone diameters of Enterobacteriaceae (E. coli, E. cloacae, K. pneumoniae) and P. aeruginosa
isolates (26 originating from the University Hospital Zurich (USZ), 29 from four different European study centers)
on MH and RPMI-1640 agar. Each isolate was tested in two independent experiments. Data show median +
interquartile range. Nonparametric Mann-Whitney Test, *** < 0.0001. Disk size: 6 mm, 15 µg azithromycin.
n = number of tested clinical isolates.
The MIC-colored zone method, as described by Kronvall et al., which we adopted and which
is used by EUCAST [20], showed significant correlation of MICs and inhibition zone diameters
(Figure 1) in RPMI-1640 medium for E. coli and E. cloacae (Kendall’s τ =−0.4279, −0.3783, p = 0.0051,




Figure 1. Increased azithromycin susceptibility of Enterobacteriaceae in RPMI-1640 medium as compared
to Mueller-Hinton medium. Azithromycin susceptibility of 28 E. coli, 24 E. cloacae and 26 K. pneumoniae
isolates in Mueller-Hinton (a); and RPMI-1640 (b); the medium was measured by disk diffusion and
broth microdilution. A MIC-colored zone method was applied to correlate the inhibition zone diameter
(mm) of each bacterial isolate with the corresponding MIC (mg/L). Kendall’s τ and p-value were
calculated for each species and medium. Each isolate was tested in two independent experiments.
Disk size: 6 mm, 15 µg azithromycin.
The inhibition zone diameter of every individual Enterobacteriaceae isolate increased on RPMI-1640
agar as compared to MH agar, and for E. coli a putative split into a more susceptible and a resistant
population seemed to occur, although corresponding numbers are low (Figure 1). Of note, clinical
carbapenemase-positive Enterobacteriaceae strains consistently showed larger azithromycin inhibition
zones on RPMI-1640 than on MH agar (Figure S1). Inhibition zones for the other antibiotics tested
(cefepime, tobramycin, clarithromycin, erythromycin, tetracycline and tigecycline) did not differ
between RPMI-1640 and MH agar in any of the examined species. In contrast to our freshly prepared
RPMI-1640 agar plates, the commercially available RPMI-1640 agar plates routinely used for mycology
assays were not suitable due to inhibition of bacterial growth. To exclude the possibility that the
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increased susceptibility found in RPMI-1640 was exclusively due to the added sodium bicarbonate,
we assessed the azithromycin MICs in MH with sodium bicarbonate in a set of four strains of each
species. Consistent with the data of Ersoy et al. [18], the MICs towards azithromycin were lower in MH
with sodium bicarbonate compared to MH without sodium bicarbonate. However, the tested isolates
remained less susceptible to azithromycin in MH with sodium bicarbonate as compared to RPMI-1640
(Table S2). Thus, we conclude that sodium bicarbonate is not the only component in RPMI-1640 leading
to lower resistance towards azithromycin.
2.2. Azithromycin Susceptibility Increased on RPMI-1640 Agar in a Subgroup of P. aeruginosa
In the 55 clinical P. aeruginosa isolates, the average azithromycin inhibition zone diameters
increased significantly on RPMI-1640 agar as compared to MH agar, although to a lower extent than
in the Enterobactericeae strains (Table 1). This was mainly due to a subgroup of strains displaying
inhibition zone diameters ranging from 6 to 12 mm with minimal difference between RPMI-1640
and MH agar. In contrast, two other delimited sub-populations showed a trend towards higher
azithromycin susceptibility on RPMI-1640 as compared to MH agar, one group ranging from 13 to






Figure 2. Increased azithromycin susceptibility in a subgroup of P. aeruginosa in RPMI-1640 medium
as compared to Mueller-Hinton medium. Azithromycin susceptibility of 55 P. aeruginosa isolates
in Mueller-Hinton (a); and RPMI-1640 (b); the medium was measured by disk diffusion and broth
microdilution. MIC-zone method was applied to correlate the inhibition zone diameter [mm] of each
bacterial isolate with the corresponding MIC (mg/L). Kendall’s τ and p-value were calculated for each
species and medium. Each isolate was tested in two independent experiments. Disk size: 6 mm,
15 µg azithromycin.
Nineteen out of the 29 clinical P. aeruginosa isolates from the European study batch derived from
cystic fibrosis patients. Ten of those isolates harbored a mutation in the gene coding for Domain V
of the 23S ribosomal subunit, which is known to confer azithromycin resistance [21]. All the isolates
containing a mutation presented with small inhibition zone diameters ranging from 6–8 mm and MICs
≥ 128 mg/L in both media, while the rest of the CF patients’ isolates showed increased susceptibility
in RPMI-1640 medium (Figure 3). None of the hospital-acquired isolates (n = 10) carried a mutation.
Testing the 26 clinical isolates collected at the University Hospital of Zurich revealed that only one
strain harbored a mutation (A2045T), which corresponded with an azithromycin-resistant phenotype
on both media measured by disk diffusion, as well as by broth microdilution. Despite displaying a
wild-type 23S rRNA gene, 15 out of 44 isolates presented with a resistant profile on MH and RPMI-1640
agar but showed lower MICs on RPMI-1640 than on MH medium (Figure 3).
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Figure 3. P. aeruginosa isolates carrying a mutation in Domain V of the 23S rRNA gene showed a
resistant profile in liquid and solid Mueller-Hinton and RPMI-1640 medium. Domain V of the 23S rRNA
gene was sequenced in 55 P. aeruginosa isolates and analyzed for known mutations conferring resistance
to macrolides (A2045T, A2045G, A2046T, A2046G and C2598T). Isolates with a wild-type Domain V of
the 23S rRNA gene were split into two subgroups according to their resistance profile on RPMI-1640
agar. Azithromycin susceptibility was measured by disk diffusion (a); and broth microdilution (b);
in Mueller-Hinton (circles) and RPMI-1640 (triangles) medium. Data show the median + interquartile
range, Nonparametric Mann-Whitney Test, *** <0.0001. Disk size: 6 mm, 15 µg azithromycin.
3. Discussion
In this study, we showed that the azithromycin susceptibility of clinical Enterobacteriaceae isolates
was higher on RPMI-1640 agar than on the routinely used MH agar. These findings take the previous
observations, showing lower MICs in liquid tissue culture media (DMEM and RPMI-1640) than in MH
broth for several bacterial species, e.g., Stenotrophomonas, a step further, setting the stage to expand
routine AST testing in the clinical microbiology laboratory [16–18,21]. To the best of our knowledge,
this is the first method comparison study comprising the most relevant Gram-negative bacterial
species regarding antibiotic susceptibility on MH and RPMI solid and liquid media. The assumption
that the growth medium has no influence on the predictive power of susceptibility testing for
therapeutic effectivity is therefore put into question; and careful evaluation and revision of in vitro
AST methods might be necessary for specific situations, such as infections with multidrug-resistant
Gram-negative bacteria.
The observed differences in susceptibility suggest the existence of determinants influencing
antibiotic susceptibility that may be active in the nutrient-rich MH agar and inactive in the more
physiological and nutrient-poor RPMI-1640 agar. Ersoy et al. previously showed that the increased
susceptibility of azithromycin, erythromycin and tetracycline in liquid DMEM was influenced by the
presence of sodium bicarbonate in DMEM [18]. Although RPMI-1640 contains similar concentrations
of sodium bicarbonate as DMEM, only the susceptibility towards azithromycin was affected in the disk
diffusion assay in our study (Table S3).
As a possible mechanism for the increased azithromycin susceptibility of P. aeruginosa in
RPMI-1640 medium, Buyck et al. proposed an increase of the outer membrane permeability. Thereby,
the macrolides are able to penetrate the membrane and, through a yet unknown mechanism, impair
the expression of oprM, the outer membrane component of one of the main efflux systems [17,22,23].
The distinct susceptibility phenotypes we observed amongst the tested P. aeruginosa strains (Figure 2;
Figure 3) suggest that RPMI-1640 medium induces additionally a specific response in distinct bacterial
populations. Such a response might be caused by point mutations in the gene coding for Domain V
of the 23S rRNA, which are known to increase resistance towards azithromycin in P. aeruginosa [24].
Mustafa et al. analyzed a collection of over 300 clinical P. aeruginosa isolates for 23S rRNA mutations
and discovered single or double mutations in 43% of the isolates with cystic fibrosis origin [21].
In contrast, no mutations were found in isolates from patients with hospital-acquired pneumonia.
In our P. aeruginosa collection, where cystic fibrosis patients were a minority, we found only one isolate
carrying a point mutation in the 23S rRNA gene. Nevertheless, additional 15 isolates without mutation
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showed similar inhibition zone diameters on both media but lower MICs in RPMI-1640 medium.
While resistance in a liquid medium correlated with the known mutations in Domain V of the 23S rRNA
gene, these mutations seemed to not be the sole determinants of decreased susceptibility on RPMI-1640
agar. Therefore, we assume that yet another mechanism is responsible for the medium-dependent shift
in susceptibility measured by disk diffusion in our clinical isolate collection.
In a murine infection model of MDR Gram-negative bacterial infections, azithromycin was found
to improve disease outcome [15,25]. Further, azithromycin was shown to reduce absolute bacterial
numbers and increase specialized metabolite production of P. aeruginosa biofilms [26]. Thus, not only
immunomodulatory effects but also impairment of planktonic and biofilm-associated bacteria may play
an important role for the beneficial effects of macrolide therapy found in patients with Gram-negative
sepsis or ventilator-associated pneumonia [9,11,26–29].
While several studies showed increased azithromycin MICs in tissue culture media as compared
to MH in various Gram-negative species, AST by disk diffusion on tissue culture medium has
not been tested so far. Comparison of the two methods revealed excellent MIC/zone correlations
on RPMI-1640 agar in E. coli, E. cloacae and P. aeruginosa, a trend was observed in K. pneumoniae.
These findings could pave the way for further expanding the well-established, accurate, simple, fast,
and reproducible disk diffusion method from MH agar to solid RPMI-1640 to the clinical microbiology
routine testing. This may broaden the potential therapeutic options in multidrug-resistant bacterial
infections, eliminating major errors in forecasting therapeutic success in susceptibility reports.
In summary, we have demonstrated that the inhibition zone diameters correlated well with the
MICs in both MH as well as RPMI-1640 medium. Azithromycin inhibition zone diameters significantly
increased on RPMI-1640 agar when tested with the disk diffusion method, both for fully susceptible as
well as multidrug-resistant Gram-negatives, including carbapenemase-producing Enterobacteriaceae.
We took previous findings a step further by rendering them applicable in the routine setting of a
clinical microbiology laboratory. Thus, we propose that for multidrug-resistant Gram-negative bacteria
additional testing conditions, which more closely reflect the host environment, e.g., cultivation on
RPMI-1640 agar, should be considered in routine testing in defined situations, such as assessing
additional therapeutic options for multidrug-resistant Gram-negative bacteria. This may unveil
additional susceptibilities to active antimicrobial substances and pave the way to clinical studies
correlating standardized in vitro AST data with therapeutic outcome in vivo in order to further assess
the therapeutic utility of macrolides in Gram-negative infections.
4. Materials and Methods
4.1. Bacterial Strains and Media
The azithromycin susceptibility of 28 Escherichia coli, 24 Enterobacter cloacae, 26 Klebsiella pneumoniae
and 26 Pseudomonas aeruginosa isolates, collected between 2014 and 2016 at the University Hospital
Zurich (USZ), was tested by disk diffusion and broth microdilution techniques. Carbapenemase-positive
isolates were collected between 2013 and 2015 (14 K. pneumoniae, 2 E. coli, 1 Proteus mirabilis, 1 Citrobacter
koseri, 1 Morganella morganii) and tested by disk diffusion. Additionally, 29 clinical P. aeruginosa isolates,
which were collected in 4 different European study centers and had previously been tested for their
susceptibility to macrolides including azithromycin by broth microdilution, [21] were now assessed by
disk diffusion. Strains were stored at −80 ◦C in LB/20% glycerol and grown in Luria Broth Lennox (LB,
Becton Dickinson, Le Pont de Claix, France) or on cation-adjusted Mueller-Hinton II (MH, BD, France)
or Roswell Park Memorial Institute agar (RPMI-1640, Gibco, Paisley, UK) in a shaking incubator at
35 ◦C, 5% CO2. RPMI-1640 was prepared according to the manufacturer’s instructions (including the
addition of 2 g/L NaHCO3), filter-sterilized, and the pH was adjusted to 7.0–7.4. RPMI-1640 agar plates
consisted of 72% RPMI-1640, 1% agar (BD, France) and 3% LB. RPMI-1640 agar plates (Biomérieux,
Marcy-L’Etoile, France) were used for comparison.
Antibiotics 2020, 9, 218 7 of 9
4.2. Disk Diffusion Testing
Disk diffusion testing was performed according to EUCAST guidelines using commercial MH agar
square plates (Becton Dickinson, Franklin Lakes, NJ, USA) and custom-made RPMI-1640 agar plates (as
described above) [30]. After placing antibiotic paper disks (azithromycin, erythromycin, clarithromycin,
tobramycin, cefepime, tetracycline, tigecycline, i2a, France; for concentrations see Table S1), plates were
incubated (18 hours, 35 ◦C) with 5% CO2 to maintain a stable plate pH since RPMI-1640 was buffered
with sodium bicarbonate. Inhibition zones were detected by the SirScan 2000 automatic plate reader
(i2a). Two independent measurements were performed on each isolate. The quality control protocol
(QC), as recommended by EUCAST for MH agar, was routinely followed also for RPMI-1640 agar to
ensure standardization of the technique and quality of the agar plates [31]. Inhibition zones of the two
EUCAST reference strains P. aeruginosa ATCC 27853 and E. coli ATCC 25922 matched EUCAST QC
requirements on MH agar plates, confirming constant quality of our testing procedure.
4.3. Broth Microdilution Susceptibility Testing
The minimal inhibitory concentration (MIC) of azithromycin in liquid MH or RPMI-1640 medium
was assessed by broth microdilution following the EUCAST protocol [32]. Differing from the EUCAST
protocol, the plates were incubated for 20 hours at 37 ◦C in a shaking incubator supplemented with 5%
CO2 to keep the pH of the RPMI-1640 medium stable. Assays were performed in duplicates.
4.4. Sequencing of the Gene Coding for Domain V of the 23S Ribosomal Subunit
Domain V of the 23S rRNA gene was amplified and sequenced as described before and screened
for the previously described mutations A2045G/T, A2046G/T and C2598G/T in P. aeruginosa strains [21].
4.5. Statistical Analysis
The statistical analysis was performed with either GraphPad Prism 7.04 (Mann-Whitney Test)
(GraphPad Software, San Diego, CA, USA) or R version 3.5.0 (Kendall rank coefficient) (GraphPad
Software, San Diego, CA, USA) software for Windows.
Supplementary Materials: The following are available online at http://www.mdpi.com/2079-6382/9/5/218/s1,
Figure S1: Increased azithromycin susceptibility in carbapenemase-positive Enterobacteriaceae on RPMI-1640
agar as compared to MH agar. Table S1: Concentration of antibiotic disks. Table S2: Decrease in resistance
towards azithromycin in RPMI-1640 or MH containing NaHCO3. Table S3: Median erythromycin and tetracycline
inhibition zone diameters of Enterobacteriaceae and P. aeruginosa on MH and RPMI-1640 agar.
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